• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

子宫外中肾样肿瘤:扩展形态学谱。

Extrauterine Mesonephric-like Neoplasms: Expanding the Morphologic Spectrum.

机构信息

Departments of Pathology.

Department of Cellular Pathology, North West London Pathology, Imperial College Healthcare NHS Trust, London.

出版信息

Am J Surg Pathol. 2022 Jan 1;46(1):124-133. doi: 10.1097/PAS.0000000000001766.

DOI:10.1097/PAS.0000000000001766
PMID:34183523
Abstract

Mesonephric-like adenocarcinomas (MLA) are rare neoplasms arising in the uterine corpus and ovary which have been added to the recent 2020 World Health Organization Classification of Female Genital Tumors. They have similar morphology and immunophenotype and exhibit molecular aberrations similar to cervical mesonephric adenocarcinomas. It is debated as to whether they are of mesonephric or Mullerian origin. We describe the clinical, pathologic, immunohistochemical, and molecular features of 5 cases of extrauterine mesonephric-like proliferations (4 ovary, 1 extraovarian), all with novel and hitherto unreported features. These include an origin of MLA in extraovarian endometriosis, an association of ovarian MLA with high-grade serous carcinoma, mixed germ cell tumor and mature teratoma, and a borderline ovarian endometrioid tumor exhibiting mesonephric differentiation. Four of the cases exhibited a KRAS variant and 3 also a PIK3CA variant. In reporting these cases, we expand on the published tumor types associated with MLA and report for the first time a borderline tumor exhibiting mesonephric differentiation. We show the value of molecular testing in helping to confirm a mesonephric-like lesion and in determining the relationship between the different neoplastic components. We provide further evidence for a Mullerian origin, rather than a true mesonephric origin, in some of these cases. We also speculate that in the 2 cases associated with germ cell neoplasms, the MLA arose out of the germ cell tumor.

摘要

苗勒管样腺癌(MLA)是一种罕见的肿瘤,发生于子宫体和卵巢,已被纳入最近的 2020 年世界卫生组织女性生殖器官肿瘤分类。它们具有相似的形态学和免疫表型,并表现出与宫颈苗勒管腺癌相似的分子异常。关于它们是来源于苗勒管还是中肾管,目前仍存在争议。我们描述了 5 例发生于子宫外的苗勒管样增生(4 例卵巢,1 例卵巢外)的临床、病理、免疫组化和分子特征,这些均具有新颖且迄今未报道的特征。这些特征包括卵巢苗勒管样腺癌起源于卵巢外子宫内膜异位症、卵巢苗勒管样腺癌与高级别浆液性癌、混合性生殖细胞肿瘤和成熟性畸胎瘤以及具有苗勒管分化的交界性卵巢子宫内膜样肿瘤的关联。4 例存在 KRAS 变异,3 例还存在 PIK3CA 变异。在报告这些病例的同时,我们扩展了与 MLA 相关的已发表的肿瘤类型,并首次报告了具有苗勒管分化的交界性肿瘤。我们展示了分子检测在帮助确认苗勒管样病变以及确定不同肿瘤成分之间关系方面的价值。在这些病例中的一些中,我们提供了更多证据表明其来源于米勒管,而不是真正的中肾管。我们还推测,在与生殖细胞肿瘤相关的 2 例中,MLA 来源于生殖细胞肿瘤。

相似文献

1
Extrauterine Mesonephric-like Neoplasms: Expanding the Morphologic Spectrum.子宫外中肾样肿瘤:扩展形态学谱。
Am J Surg Pathol. 2022 Jan 1;46(1):124-133. doi: 10.1097/PAS.0000000000001766.
2
Ovarian Combined Low-grade Serous and Mesonephric-like Adenocarcinoma: Further Evidence for A Mullerian Origin of Mesonephric-like Adenocarcinoma.卵巢低级别浆液性和中肾样混合性腺癌:中肾样腺癌来源于苗勒管的进一步证据。
Int J Gynecol Pathol. 2020 Jan;39(1):84-92. doi: 10.1097/PGP.0000000000000573.
3
Targeted Genomic Profiling Reveals Recurrent KRAS Mutations in Mesonephric-like Adenocarcinomas of the Female Genital Tract.靶向基因组分析揭示女性生殖器官中苗勒管样腺癌的 KRAS 基因突变。
Am J Surg Pathol. 2018 Feb;42(2):227-233. doi: 10.1097/PAS.0000000000000958.
4
Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study.妇科生殖道中中肾管腺癌和中肾管样腺癌的临床病理特征:一项多机构研究。
Am J Surg Pathol. 2021 Apr 1;45(4):498-506. doi: 10.1097/PAS.0000000000001612.
5
Premature Classification of Early-stage Endometrioid Ovarian Carcinoma With Mesonephric-like Differentiation as Mesonephric-like Adenocarcinoma.将具有中肾样分化的早期子宫内膜样卵巢癌过早分类为中肾样腺癌。
Int J Gynecol Pathol. 2024 Jul 1;43(4):362-372. doi: 10.1097/PGP.0000000000001002. Epub 2024 Mar 4.
6
Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.卵巢子宫内膜样癌和高级别浆液性癌的中肾样分化:与中肾样腺癌相比,其临床病理和分子特征不同。
Anticancer Res. 2021 Sep;41(9):4587-4601. doi: 10.21873/anticanres.15272.
7
A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract.GATA3、TTF1、CD10 和 Calretinin 在鉴别妇科移行细胞及移行细胞样癌中的比较。
Am J Surg Pathol. 2018 Dec;42(12):1596-1606. doi: 10.1097/PAS.0000000000001142.
8
Ovarian Combined Serous Borderline Tumor/Low-grade Serous Carcinoma and Mesonephric-like Lesion: Report of 2 Cases With New Observations.卵巢交界性浆液性囊腺瘤/低级别浆液性癌合并中肾样瘤:2 例病例报告及新观察。
Int J Gynecol Pathol. 2023 Mar 1;42(2):182-191. doi: 10.1097/PGP.0000000000000868. Epub 2022 May 20.
9
Mesonephric Adenocarcinoma and Mesonephric-like Adenocarcinoma of the Urinary Tract.尿路中肾胚细胞瘤和肾胚细胞瘤样腺癌。
Mod Pathol. 2023 Jan;36(1):100031. doi: 10.1016/j.modpat.2022.100031.
10
Ovarian mesonephric-like adenocarcinoma arising in serous borderline tumor: a case report with complex morphological and molecular analysis.卵巢中肾样腺癌源于浆液性交界性肿瘤:一例具有复杂形态学和分子分析特征的病例报告。
Diagn Pathol. 2020 Jul 21;15(1):91. doi: 10.1186/s13000-020-01012-z.

引用本文的文献

1
Immune microenvironment heterogeneity characterizes biologically distinct KRAS/SPOP and KRAS/PIK3CA mesonephric-like adenocarcinoma subtypes revealed by integrated whole-exome and transcriptomic profiling.免疫微环境异质性表征了通过全外显子组和转录组联合分析揭示的生物学上不同的KRAS/SPOP和KRAS/PIK3CA中肾样腺癌亚型。
Front Immunol. 2025 Jul 16;16:1605227. doi: 10.3389/fimmu.2025.1605227. eCollection 2025.
2
Papillary and ductal patterns of mesonephric-like adenocarcinomas are often overlooked: a retrospective revaluation of over 1000 endometrial carcinomas.中肾样腺癌的乳头样和导管样模式常被忽视:对1000多例子宫内膜癌的回顾性重新评估
Histopathology. 2025 May;86(6):862-877. doi: 10.1111/his.15393. Epub 2024 Dec 17.
3
Ovarian Mesonephric-like Adenocarcinoma: Its Prevalence in a Japanese High-Volume Cancer Center and a Literature Review on Therapeutic Targets.
卵巢中肾样腺癌:在日本大容量癌症中心的流行情况及其治疗靶点的文献复习。
Curr Oncol. 2024 Aug 30;31(9):5107-5120. doi: 10.3390/curroncol31090378.
4
Mesonephric-type adenocarcinomas of the ovary: prevalence, diagnostic reproducibility, outcome, and value of PAX2.卵巢中肾型腺癌:流行率、诊断可重复性、结局以及 PAX2 的价值。
J Pathol Clin Res. 2024 Jul;10(4):e12389. doi: 10.1002/2056-4538.12389.
5
Mesonephric-like adenocarcinoma of the female genital tract: possible role of KRAS-targeted treatment-detailed molecular analysis of a case series and review of the literature for targetable somatic KRAS-mutations.女性生殖道中肾样腺癌:KRAS 靶向治疗的可能作用——一系列病例的详细分子分析及针对可靶向体细胞 KRAS 突变的文献复习。
J Cancer Res Clin Oncol. 2023 Nov;149(17):15727-15736. doi: 10.1007/s00432-023-05306-9. Epub 2023 Sep 5.
6
Mesonephric Adenomyofibroma: A Biphasic Vaginal Mass of Mesonephric Type With Molecular Analysis: A Case Report of a Rare Entity.中肾性腺瘤样纤维瘤:具有中肾型的双相阴道肿块伴分子分析:一种罕见实体的病例报告。
Int J Gynecol Pathol. 2023 Sep 1;42(5):523-528. doi: 10.1097/PGP.0000000000000945. Epub 2023 Jan 26.
7
Mesonephric-Like Adenocarcinomas a Rare Tumor: The Importance of Diagnosis.中肾样腺癌:一种罕见的肿瘤,诊断至关重要。
Int J Environ Res Public Health. 2022 Nov 4;19(21):14451. doi: 10.3390/ijerph192114451.
8
Mucinous Borderline Tumor Associated with Mesonephric-like Proliferation: Further Evidence for a Possible New Origin of Ovarian Mucinous Neoplasms.伴中肾样增生的黏液性交界性肿瘤:卵巢黏液性肿瘤可能新起源的进一步证据
Diagnostics (Basel). 2022 Aug 5;12(8):1901. doi: 10.3390/diagnostics12081901.
9
Somatic mutation analysis of Mesonephric-Like adenocarcinoma and associated putative precursor Lesions: Insight into pathogenesis and potential molecular treatment targets.中肾样腺癌及相关假定前驱病变的体细胞突变分析:对发病机制及潜在分子治疗靶点的见解
Gynecol Oncol Rep. 2022 Jul 19;42:101049. doi: 10.1016/j.gore.2022.101049. eCollection 2022 Aug.
10
Mesonephric-Like Adenocarcinoma of Uterine Corpus: A Clinicopathological and Targeted Genomic Profiling Study in a Single Institution.子宫体类中肾管腺癌:单中心临床病理及靶向基因组分析研究
Front Oncol. 2022 Jul 5;12:911695. doi: 10.3389/fonc.2022.911695. eCollection 2022.